Managing Your Patients with Psoriasis and IBD: A Conversation with the Experts


Anita Afzali, MD, MPH, MHCM, FACG, AGAF
Professor of Clinical Medicine
Interim Chief, Division of Digestive Diseases
Executive Vice Chair, Department of Internal Medicine
University of Cincinnati College of Medicine
Associate Chief Medical Officer, UC Health System
Cincinnati, OH
Anita Afzali, MD, MPH, MHCM, FACG, AGAF

Anita Afzali, MD, MPH, MHCM, is a Professor of Clinical Medicine and a gastroenterologist that specializes in Inflammatory Bowel Disease (IBD). She has recently transitioned to the University of Cincinnati after successfully building the first standalone multidisciplinary IBD Center and serving as the Medical Director at The Ohio State University Wexner Medical Center for five years. Dr. Afzali is now the Executive Vice Chair of the Department of Internal Medicine at the University of Cincinnati and Associate Chief Medical Officer of UC Health Systems and Cincinnati Children’s Hospital. She received her medical degree and completed both an Internal Medicine residency and Gastroenterology fellowship at the University of Washington in Seattle, WA. While in fellowship, Dr. Afzali worked in outcomes research and epidemiology and graduated with a Master’s in Public Health. She recently obtained an additional Master’s in Health Care Management for physician executive leadership and business administration from Harvard University. Her areas of research interest include clinical outcomes and clinical trials for investigative therapies and diagnostics in IBD. She is a healthcare redesign leader with interests in clinical operations and transformative medical care delivery. Dr. Afzali has extensive peer-reviewed publications and is a clinical trialist in over 20 investigative drug and diagnostic trials. She is also an invited lecturer on national and international programs and serves on several international advisory boards and scientific committees. Dr. Afzali is the incoming Chair of the American College of Gastroenterology (ACG) Educational Affairs Committee and the incoming Chair of the World Gastroenterology Organization (WGO) Publications Committee, as well as Co-Editor of the WGO quarterly global newsletters.

Statement of Need

For patients with psoriasis (PsO), the implementation of effective medication regimens can be life changing. However, patients diagnosed with PsO are also at increased risk for the development of inflammatory bowel disease (IBD), including both ulcerative colitis and Crohn’s disease. Targeted anti-IL-17 therapies have demonstrated efficacy in the treatment of PsO but have been associated with either new or worsening IBD. It is imperative that clinicians treating patients with either isolated PsO or cooccurring PsO and IBD recognize which treatment options optimize efficacy and safety for patients in both groups.

In this CME Outfitters BriefCase, expert Dr. Anita Afzali will utilize case-based learning to illustrate the common features and pathophysiologic mechanisms underlying these two inflammatory disorders. Faculty will translate clinical data to help clinicians to select optimal treatments aimed at improving outcomes for patients impacted by PsO and IBD.

Learning Objectives

  • Assess the genetic, pathophysiologic, and other links between PsO and IBD.
  • Select appropriate pharmacotherapeutic treatment for patients with co-existing PsO and IBD.

Financial Support

Supported by an educational grant from Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC.

Target Audience

Physicians, physician associates (PAs), nurse practitioners (NPs), nurses, and pharmacists specializing in gastroenterology, dermatology, or primary care.

Credit Information

Jointly Accredited Provider

In support of improving patient care, CME Outfitters, LLC, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Interprofessional (IPCE) 0.75

This activity was planned by and for the healthcare team, and learners will receive 0.75 Interprofessional Continuing Education (IPCE) credit for learning and change.

Physicians (ACCME) 0.75

CME Outfitters, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. CME Outfitters, LLC, designates this enduring activity for a maximum of .75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.


Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.75 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Nurses (ANCC) 0.5

This activity is designated for 0.5 contact hours.

Note for California Nurses

This continuing nursing education activity was approved by the California Board of Registered Nursing. CME Outfitters LLC’s provider number is CEP15510.

PAs (AAPA) 0.75

CME Outfitters, LLC, has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 0.75 AAPA Category 1 CME credits. Approval is valid until expiration date listed above. PAs should only claim credit commensurate with the extent of their participation.

Pharmacists/Pharmacy Tech (ACPE) 0.75

This application-based activity is approved for 0.75 contact hour (0.075 CEUs) of continuing pharmacy credit.
Activity UAN: JA0007185-0000-23-031-H01-P

MIPS Improvement Activity

This activity counts towards MIPS Improvement Activity requirements under the Medicare Access and CHIP Reauthorization Act of 2015 (MACRA). Clinicians should submit their improvement activities by attestation via the CMS Quality Payment Program website.

Royal College MOC

Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.

Disclosure Declarations

It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. CME Outfitters, LLC, has evaluated, identified, and mitigated any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process.

Dr. Afzali reports the following financial relationships:

Advisory Board: AbbVie Inc.; Bristol Myers Squibb Company; Gilead Sciences, Inc.; Janssen Pharmaceuticals, Inc.; Lilly; Pfizer Inc.; and Takeda Pharmaceuticals U.S.A., Inc.

Consultant: AbbVie Inc.; Bristol Myers Squibb Company; Janssen Pharmaceuticals, Inc.; Lilly; Pfizer Inc.; and Takeda Pharmaceuticals U.S.A., Inc.

Speakers Bureau: AbbVie Inc. Bristol Myers Squibb Company; Janssen Pharmaceuticals, Inc.; Pfizer Inc.; and Takeda Pharmaceuticals U.S.A., Inc.

Other Financial or Material Support: IBDHorizons – Founder, Board Member and Scrubs & Heels – Founder, Board Member

Disclosures were obtained from the CME Outfitters, LLC staff: No disclosures to report:

  • Jeffrey Helfand, DO (peer reviewer)
  • Morgan Stockberger, MD (planning committee)
  • John Jones, PharmD (planning committee)
  • Susan H. Yarbrough, CHCP (planning committee)
  • Sandra Caballero, PharmD (planning committee)
  • Sharon Tordoff (planning committee)

Faculty of this CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices.

Obtaining Credit

Post-tests, credit request forms, and activity evaluations must be completed online (requires free account activation), and participants can print their certificate or statement of credit immediately (75% pass rate required). This website supports all browsers except Internet Explorer for Mac. For complete technical requirements and privacy policy, visit our Privacy & Confidentiality page.

Questions about this activity?

Call us at 877.CME.PROS (877.263.7767).


Managing Your Patients with Psoriasis and IBD: A Conversation with the Experts
Event Date: 04/12/2023